FATE
NASDAQ
US
Fate Therapeutics, Inc. - Common Stock
$1.22
▼ $-0.02
(-1.61%)
Vol 660K
3
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$113.3M
ROE
-56.6%
Margin
-2187.1%
D/E
0.00
Beta
2.23
52W
$1–$2
Wall Street Consensus
18 analysts · Apr 20265
Strong Buy
6
Buy
7
Hold
0
Sell
0
Strong Sell
61.1%
Buy Rating
Price Chart
Similar Stocks
HRTX
Heron Therapeutics Inc
$238.4M
UNCY
Unicycive Therapeutics Inc
$124.0M
DTIL
Precision BioSciences Inc
$100.1M
SPRO
Spero Therapeutics Inc
$131.3M
CBUS
Cibus Inc
$94.5M
BDTX
Black Diamond Therapeutics Inc
P/E 6.4
$138.4M
KLRS
Kalaris Therapeutics Inc
$141.3M
AGEN
Agenus Inc
$106.8M
EQ
Equillium Inc
$94.4M
Earnings
Beat rate: 100.0%
Next Report
May 11, 2026
EPS Estimate: $-0.29
| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Mar 2026 | $-0.29 | — | — |
| Dec 2025 | $-0.28 | $-0.27 | +$0.01 |
| Sep 2025 | $-0.30 | $-0.27 | +$0.03 |
| Jun 2025 | $-0.35 | $-0.29 | +$0.06 |
Quarterly Revenue & Earnings
| Quarter | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|
| Revenue | $1.9M | $1.6M | $1.9M | $1.7M | $1.4M |
| Net Income | -$52.2M | -$37.6M | -$34.1M | -$32.2M | -$32.4M |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -55.7% | -55.7% | -55.7% | -55.7% | -56.6% | -56.6% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | -1786.6% | -2025.0% | -2025.0% | -2025.0% | -2187.1% | -2187.1% |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 8.04 | 8.04 | 8.04 | 8.04 | 7.87 | 7.87 |
Key Ratios
ROA (TTM)
-40.2%
P/S (TTM)
15.88
P/B
0.6
EPS (TTM)
$-1.32
CF/Share
$-1.58
Rev Growth 3Y
-37.5%
52W High
$1.99
52W Low
$0.66
$0.66
52-Week Range
$1.99
Financial Health
Free Cash Flow
-$24.5M
Net Debt
$31.2M
Cash
$46.6M
Total Debt
$77.8M
As of Dec 31, 2025
How does FATE compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
FATE valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
15.9
▲
24%
above
peers
(12.9)
vs Peers
vs Industry
Pricier
P/B ratio
0.6
▼
76%
below
peers
(2.5)
vs Peers
vs Industry
Undervalued
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
FATE profitability vs Biotechnology peers
ROE
-56.6%
▲
16%
above
peers
(-67.3%)
vs Peers
vs Industry
Below avg
Net margin
-2187.1%
▼
663%
below
peers
(-286.8%)
vs Peers
vs Industry
Weak
Gross margin
—
▼
0%
below
peers
(78.6%)
vs Peers
vs Industry
In line
ROA
-40.2%
▲
14%
above
peers
(-46.7%)
vs Peers
vs Industry
In line
FATE financial health vs Biotechnology peers
D/E ratio
0.0
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
Low debt
Current ratio
7.9
▲
77%
above
peers
(4.4)
vs Peers
vs Industry
Strong liquidity
Beta
2.2
▲
130%
above
peers
(1.0)
vs Peers
vs Industry
More volatile
FATE fundamentals radar
FATE
Peer median
Industry
FATE profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio